Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASAD for Clostridium Difficile Infection
NCT01570634Phase 2Terminated
- Sponsor
- Salient Pharmaceuticals
- Start
- Mar 2012
- Primary completion
- Sep 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of calcium aluminosilicate in Clostridioides difficile infection (CDI), sponsored by Salient Pharmaceuticals. Started Mar 2012; status: terminated.
02
Drugs
calcium aluminosilicate
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT01570634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01570634.